Intravenous Immunoglobulin Market Report: Trends, Forecast and Competitive Analysis to 2030

Intravenous Immunoglobulin Trends and Forecast

The future of the global intravenous immunoglobulin market looks promising with opportunities in the hospital, homecare, and specialty clinic markets. The global intravenous immunoglobulin market is expected to reach an estimated $24.6 billion by 2030 with a CAGR of 7.6% from 2024 to 2030. The major drivers for this market are increasing geriatric population, rising number of hemophiliacs, and new technologies related to the generation of immunoglobulin, and improved purification methods (with improved plasma yield).

A more than 150-page report is developed to help in your business decisions.

Intravenous Immunoglobulin by Segment

The study includes a forecast for the global intravenous immunoglobulin by application, distribution channel, end use, form, and region.

Intravenous Immunoglobulin Market by Application [Shipment Analysis by Value from 2018 to 2030]:

• Hypogammaglobulinemia
• CIPD
• Immunodeficiency Diseases
• Congenital AIDs
• Chronic Lymphocytic Leukemia
• Myasthenia Gravis
• Multifocal Motor Neuropathy
• Kawasaki Disease
• Guillain-Barre Syndrome
• Others

Intravenous Immunoglobulin Market by Distribution Channel [Shipment Analysis by Value from 2018 to 2030]:

• Intravenous
• Subcutaneous

Intravenous Immunoglobulin Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

• Hospitals
• Homecare
• Specialty Clinics
• Others

Intravenous Immunoglobulin Market by Form [Shipment Analysis by Value from 2018 to 2030]:

• Liquid
• Lyophilized

Intravenous Immunoglobulin Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

List of Intravenous Immunoglobulin Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies intravenous immunoglobulin companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the intravenous immunoglobulin companies profiled in this report include-

• Baxter
• Bayer
• Merck
• Biotest
• Top Bio
• CSL
• Octapharma
• Grifols
• Kedrion
• Takeda Pharmaceuical

Intravenous Immunoglobulin Market Insights

Lucintel forecasts that immunodeficiency diseases will remain the largest segment over the forecast period due to increasing focus towards the diagnosis and treatment based on individual patient and training of patients as most of the patients are not adaptable towards self administration.

Within this market, hospital will remain the largest segment due to the increasing prevalence of primary immunodeficiency and hepatitis c, as well as other diseases, has led to surge in hospitalizations around the world, thus increasing the demand for hospital pharmacies.

North America will remain the largest region due to growing demand of therapies among clinicians, rising healthcare expenditure, and presence of major players in the region.

Features of the Global Intravenous Immunoglobulin Market

Market Size Estimates: Intravenous immunoglobulin market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Intravenous immunoglobulin market size by various segments, such as by application, distribution channel, end use, form, and region in terms of value ($B).

Regional Analysis: Intravenous immunoglobulin market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different applications, distribution channels, end uses, forms, and regions for the intravenous immunoglobulin market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the intravenous immunoglobulin market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1 What is the intravenous immunoglobulin market size?

Answer: The global intravenous immunoglobulin market is expected to reach an estimated $24.6 billion by 2030.

Q.2 What is the growth forecast for intravenous immunoglobulin market?

Answer: The global intravenous immunoglobulin market is expected to grow with a CAGR of 7.6% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the intravenous immunoglobulin market?

Answer: The major drivers for this market are increasing geriatric population, rising number of hemophiliacs, and new technologies related to the generation of immunoglobulin, and improved purification methods (with improved plasma yield).

Q4. What are the major segments for intravenous immunoglobulin market?

Answer: The future of the global intravenous immunoglobulin market looks promising with opportunities in the hospital, homecare, and specialty clinic markets.

Q5. Who are the key intravenous immunoglobulin market companies?

Answer: Some of the key intravenous immunoglobulin companies are as follows:

• Baxter
• Bayer
• Merck
• Biotest
• Top Bio
• CSL
• Octapharma
• Grifols
• Kedrion
• Takeda Pharmaceuical

Q6. Which intravenous immunoglobulin market segment will be the largest in future?

Answer: Lucintel forecasts that immunodeficiency diseases will remain the largest segment over the forecast period due to increasing focus towards the diagnosis and treatment based on individual patient and training of patients as most of the patients are not adaptable towards self administration.

Q7. In intravenous immunoglobulin market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region due to growing demand of therapies among clinicians, rising healthcare expenditure, and presence of major players in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the intravenous immunoglobulin market by application (hypogammaglobulinemia, CIPD, immunodeficiency diseases, congenital aids, chronic lymphocytic leukemia, myasthenia gravis, multifocal motor neuropathy, kawasaki disease, guillain-barre syndrome, and others), distribution channel (intravenous and subcutaneous), end use (hospitals, homecare, specialty clinics, and others), form (liquid and lyophilized), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?